Three women's-health funding announcements landed between September 30 and October 2, 2026. None is large, but each targets a specific, under-served condition with intimate-health overlap.

Why It Matters

Recurrent UTIs are one of the most common intimate-health complaints, and many cases are triggered by sex ("honeymoon cystitis"). Diagnosis, not treatment, is where money is being lost: culture-negative patients cycle through antibiotics with no answer. Biotia's investor list matters as much as the amount. VillageMD's founders built a primary-care network, and their backing suggests the plan is to put the test in front of primary-care and urogynecology referral pathways, with reimbursement as the next goal. Flouria and Know Your Floors fit two trends we've tracked all month. European hormonal-health clinics are raising small seed rounds to build country-by-country (see our September femtech-seeds roundup). Pelvic-floor care is shifting toward low-cost software, a challenge to $100–$200 connected Kegel trainers at a time when the science on Kegels is already being questioned. Across all three: these are small checks for specific problems, not platform bets, which is what the women's-health funding market looks like in late 2026.

Biotia: $9M for chronic-UTI diagnostics (October 1). New York clinical-metagenomics company Biotia announced an oversubscribed $9 million financing that its press release says exceeds its previously announced Series A. Its BIOTIA-ID Urine Test identifies the cause of recurrent and complicated urinary tract infections, which standard cultures often miss, and the company claims 97% sensitivity and 99% specificity. The test is available in all 50 states from Biotia's CLIA-certified lab. Investors include VillageMD co-founders Tim Barry (who joins the board) and Dr. Clive Fields (board observer), along with Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital and Red Bear Angels/Ventures. DigitalDx CEO Michele Colucci becomes board chair, and women's-urology specialist Dr. Angelish Kumar and Kindra founder Catherine Balsam-Schwaber join as advisors. The money will scale the lab, add women's-health tests and expand into orthopedic diagnostics. Biotia is a spinout of the Jacobs Technion-Cornell Institute at Cornell Tech.

Flouria Health: €1.5M total for a Dutch hormonal-health clinic (October 2). Flouria received an investment from Healthy.Capital that brings its total funding to €1.5 million, Femtech Insider and Dealroom reported. The amount of the new tranche was not disclosed. Flouria runs a doctor-led digital clinic for perimenopause, PMOS and postpartum recovery, with testing, tracking and personalized treatment plans. It says it has treated more than 1,000 patients since launching in 2025, and it will use the money to grow in the Netherlands and expand into other European markets. "Women's hormonal health is not a niche market, it's an underserved majority," said co-founder and CEO Jeanine van Munster.

Know Your Floors: £75K Innovate UK grant for a pelvic-floor app (September 30). Newcastle pelvic-health physiotherapist Suzanne Vernazza won £75,000 through an Innovate UK Women in Innovation Award to develop the Know Your Floors app. The app combines daily pelvic-floor exercises, gamification and education with an AI-supported information tool that will go through clinical validation, FemTech World reported. Vernazza already runs the #SqueezeAlong community, which has more than 670,000 followers. Beta testing begins in December 2026.

Sources

Update — 2026-10-03

Initial entry — story first created.